Navigation Links
Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
Date:7/29/2011

DURHAM, N.C., July 29, 2011 /PRNewswire/ -- Argos Therapeutics, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the company.

Lazard Capital Markets LLC and Canaccord Genuity Inc. are acting as joint book-running managers for the offering.  Needham & Company, LLC and BMO Capital Markets Corp. are acting as co-managers.  

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction

The offering will be made only by means of a prospectus.  When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Lazard Capital Markets, Attn: Syndicate Department, 30 Rockefeller Plaza, 60th Floor, New York, NY 10020, phone: (800) 542-0970 or Canaccord Genuity, Attn: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110, phone: (800) 225-6201.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's den
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
2. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
3. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
4. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
5. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
6. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
7. Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market
8. Michael Showalter Joins Prime Therapeutics As Chief Marketing Officer
9. Chimerix to Present at Infocasts 9th Annual Biodefense Vaccines & Therapeutics Conference
10. Life Technologies Develops Potent Drug Delivery Technology for Therapeutics Market
11. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... is being recalled after Health Canada tests confirmed it ... health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health ... recalling the product from retail stores across ... building purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)... Dec. 24, 2014  Actavis plc (NYSE: ... has received a complete response letter from the ... New Drug Application (NDA) for the fixed-dose combination ... of hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... in the receipt of a complete response letter, ...
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12
... of stent timing and type, prasugrel bests clopidogrel, ... shown to block,platelet activity in patients with acute ... cut by more than half the risk of,thrombosis, ... a new,analysis of data from the Trial to ...
... With drug-eluting stents, is the ,crush, or ,culotte, technique ... performed for an,arterial narrowing at the branchpoint of two ... be challenging to achieve full coverage of,both vessels without ... study,will provide interventional cardiologists with new information on which ...
Cached Medicine Technology:TRITON-TIMI 38 Stent Analysis Favors Prasugrel 2TRITON-TIMI 38 Stent Analysis Favors Prasugrel 3Stenting Techniques Vie in Branchpoint Lesions 2
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a ... producing and marketing of a series of induction heating ... new series of induction brazing equipments . , ... induction brazing refers to the joining of two ... heat. The manager says that there are fundamental differences ...
(Date:12/25/2014)... The microscopy market is estimated to grow at ... by 2019. Optical microscopy is the largest segment ... segment is expected to show the fastest growth ... nanotechnology, technological advancements, and increasing federal support to ... Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... Today, the business announces a click strand woven ... 30, 2015. , Click strand woven bamboo flooring ... a well-known brand in the bamboo industry. It ... reliable bamboo flooring supplier. , “We are happy ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... anti-cancer drug which is typically used for treating colorectal ... for treating gastric cancer and pancreatic cancer. TS-1 is ... was first approved in 1999 in Japan for the ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... (HealthDay News) -- Cotton swabs offer a cheap, effective ... Daily use of dry cotton swabs to gently ... dramatically reduced surgical site infections, the study revealed. Only ... developed infections, compared with 19 percent of patients in ...
... News) -- The number of U.S. workers aged 16 and ... than half over the past two decades -- from 14 ... 2009, a new study reveals. "Although the prevalence of ... lead exposure are well characterized," researchers from the U.S. Centers ...
... University of Gothenburg, have identified a series of ... carry specific sugar molecules, are found in greater concentrations ... in patients with dementia caused by other diseases. This ... future. , Gran Larson is a professor at the ...
... bacteria are proving effective platforms for delivering medicines and ... building blocks for tiny battery electrodes and computer data ... research over the last two decades, with explanations aimed ... and outside the field, is described in a new ...
... N.C. June 30, 2011 Insomnia is the ... of the adult population in the United States on ... Center is conducting the first ever, randomized, controlled clinical ... treat people with insomnia. Brainwave Optimization is a non-invasive ...
... children who watch adverts for unhealthy food on television are more ... study by researchers in the Institute of Psychology, Health and Society ... six to 13 years old from the North West of England. ... cartoon before being shown it again two weeks later. In ...
Cached Medicine News:Health News:Cotton Swabs Help Prevent Surgical Site Infections: Study 2Health News:On-the-Job Lead Exposures Falling, But Still a Problem: CDC 2Health News:New clues to the cause of Alzheimer's disease 2Health News:Turning agents of disease into tools for health and better living 2Health News:Wake Forest Baptist conducts clinical study for insomnia using new technology 2Health News:TV food advertising increases children's preference for unhealthy foods 2
... Plate Shaker with Timer are designed to give ... & 384-well microplates. The on/off button, power supply ... the side of the unit. The speed knob ... for adjustment of speed from a minimum 950 ...
Microplate incubator shaker used in a variety of immunoassay and research procedures requiring microplates....
Multiparameter laser and arc lamp flow cytometer for all applications in immunology, microbiology, cell biology, pathology, hematology, lymphocyte dubset and cell analysis....
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
Medicine Products: